GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » U-Neuron Biomedical Inc (ROCO:6973) » Definitions » Liabilities-to-Assets

U-Neuron Biomedical (ROCO:6973) Liabilities-to-Assets : 0.06 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is U-Neuron Biomedical Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. U-Neuron Biomedical's Total Liabilities for the quarter that ended in Dec. 2023 was NT$31.20 Mil. U-Neuron Biomedical's Total Assets for the quarter that ended in Dec. 2023 was NT$523.17 Mil. Therefore, U-Neuron Biomedical's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.06.


U-Neuron Biomedical Liabilities-to-Assets Historical Data

The historical data trend for U-Neuron Biomedical's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U-Neuron Biomedical Liabilities-to-Assets Chart

U-Neuron Biomedical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
0.11 0.08 0.12 0.06

U-Neuron Biomedical Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets 0.08 - 0.12 0.03 0.06

Competitive Comparison of U-Neuron Biomedical's Liabilities-to-Assets

For the Biotechnology subindustry, U-Neuron Biomedical's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


U-Neuron Biomedical's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's Liabilities-to-Assets falls into.



U-Neuron Biomedical Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

U-Neuron Biomedical's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=31.202/523.169
=0.06

U-Neuron Biomedical's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=31.202/523.169
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


U-Neuron Biomedical  (ROCO:6973) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


U-Neuron Biomedical Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of U-Neuron Biomedical's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


U-Neuron Biomedical (ROCO:6973) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.

U-Neuron Biomedical (ROCO:6973) Headlines

No Headlines